Davita (NYSE: DVA) has recently received a number of price target changes and ratings updates:

  • 12/12/2017 – Davita was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating. They now have a $82.00 price target on the stock, up previously from $63.00.
  • 12/11/2017 – Davita was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $82.00 price target on the stock, up previously from $67.71.
  • 12/7/2017 – Davita had its price target raised by analysts at J P Morgan Chase & Co from $4.90 to $84.00. They now have a “strong-buy” rating on the stock.
  • 12/7/2017 – Davita was given a new $70.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “hold” rating on the stock.
  • 12/7/2017 – Davita was upgraded by analysts at Raymond James Financial, Inc. from an “outperform” rating to a “strong-buy” rating. They now have a $84.00 price target on the stock, up previously from $65.00.
  • 12/6/2017 – Davita had its “hold” rating reaffirmed by analysts at KeyCorp.
  • 11/13/2017 – Davita had its “hold” rating reaffirmed by analysts at KeyCorp.
  • 11/10/2017 – Davita had its “hold” rating reaffirmed by analysts at Robert W. Baird. They now have a $63.00 price target on the stock.
  • 11/8/2017 – Davita had its price target lowered by analysts at Bank of America Corp from $75.00 to $66.00. They now have a “neutral” rating on the stock.
  • 11/8/2017 – Davita had its price target lowered by analysts at Royal Bank of Canada from $64.00 to $60.00. They now have a “sector perform” rating on the stock.
  • 10/23/2017 – Davita was upgraded by analysts at Wolfe Research from a “market perform” rating to an “outperform” rating.

Shares of Davita Inc (NYSE DVA) opened at $69.03 on Friday. The firm has a market cap of $13,321.91, a price-to-earnings ratio of 20.11, a price-to-earnings-growth ratio of 14.20 and a beta of 0.97. The company has a current ratio of 1.40, a quick ratio of 1.35 and a debt-to-equity ratio of 1.79. Davita Inc has a 12-month low of $52.51 and a 12-month high of $71.47.

Davita (NYSE:DVA) last posted its earnings results on Tuesday, November 7th. The company reported $0.81 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by ($0.13). Davita had a return on equity of 13.31% and a net margin of 3.40%. The company had revenue of $3.92 billion during the quarter, compared to analysts’ expectations of $3.91 billion. During the same period in the prior year, the business posted $0.95 earnings per share. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. equities research analysts expect that Davita Inc will post 3.42 earnings per share for the current fiscal year.

In other news, insider James K. Hilger sold 5,608 shares of the firm’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $69.46, for a total value of $389,531.68. Following the completion of the sale, the insider now directly owns 47,649 shares of the company’s stock, valued at approximately $3,309,699.54. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Charles Berg sold 7,048 shares of the firm’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $69.24, for a total transaction of $488,003.52. Following the completion of the sale, the insider now directly owns 5,359 shares of the company’s stock, valued at $371,057.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 117,937 shares of company stock valued at $8,028,379. Corporate insiders own 2.10% of the company’s stock.

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Receive News & Ratings for Davita Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita Inc and related companies with MarketBeat.com's FREE daily email newsletter.